Residual amount of Vancomycin hydrochloride (cas 1404-93-9) in vials after use
-
Add time:09/05/2019 Source:sciencedirect.com
We macroscopically observed vials of Vancomycin hydrochloride (cas 1404-93-9) (VCM) for injection (0.5 g/vial) dissolved in various solvents, and determined the presence or absence of residual VCM crystals. In addition, the residual VCM in vials after use was measured using a bioassay. In vials evaluated after use, the percentage of vials in which VCM crystals were macroscopically confirmed, the mean residual amount of VCM in the vials (residual %), and the percentage of vials with ≥50 mg (10 %) of residual VCM were 28.1 %, 15.0 ± 7.5 mg (3.0 %), and 0 %, respectively, after the dissolution of a single VCM vial in 10 ml of distilled water for injection (n = 57); 63.8 %, 30.2 ± 19.1 mg (6.0 %), and 16.1 %, respectively, after the dissolution of a single VCM vial in 100 ml of physiological saline (n = 224); and 72.2 %, 38.5 ± 28.0 mg (7.7 %), and 33.3 %, respectively, after the dissolution of two VCM vials in 100 ml of physiological saline (n = 18). The mean residual VCM amount was greater when using physiological saline than when using distilled water for injection as a solvent. These results show the need to follow the dissolution method described in the package insert, which calls for the addition of 10 ml of distilled water for injection to each 0.5 g VCM vial.
We also recommend Trading Suppliers and Manufacturers of Vancomycin hydrochloride (cas 1404-93-9). Pls Click Website Link as below: cas 1404-93-9 suppliers
Prev:Original Research PaperLiposomes for systematic delivery of Vancomycin hydrochloride (cas 1404-93-9) to decrease nephrotoxicity: Characterization and evaluation
Next:Cradle-to-gate life cycle inventory of Vancomycin hydrochloride (cas 1404-93-9)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- A novel dressing for the combined delivery of platelet lysate and Vancomycin hydrochloride (cas 1404-93-9) to chronic skin ulcers: Hyaluronic acid particles in alginate matrices09/08/2019
- Controlled release of Vancomycin hydrochloride (cas 1404-93-9) from a composite structure of polymeric films and porous fibers on implants09/07/2019
- Cradle-to-gate life cycle inventory of Vancomycin hydrochloride (cas 1404-93-9)09/06/2019
- Original Research PaperLiposomes for systematic delivery of Vancomycin hydrochloride (cas 1404-93-9) to decrease nephrotoxicity: Characterization and evaluation09/04/2019
- Chitosan coated Vancomycin hydrochloride (cas 1404-93-9) liposomes: Characterizations and evaluation09/03/2019
- Original ArticleStability-indicating spectrofluorimetric method with enhanced sensitivity for determination of Vancomycin hydrochloride (cas 1404-93-9) in pharmaceuticals and spiked human plasma: Application to degradation kinetics09/02/2019
- A hydrogel/fiber scaffold based on silk fibroin/oxidized pectin with sustainable release of Vancomycin hydrochloride (cas 1404-93-9)09/01/2019
-
Health and Chemical more >